Amgen | Jotup

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Retrieved on:

Monday, March 18, 2024

Novartis, NDA, Messenger, Greater China, HKEX, File, Vaccine, Amgen, Marketing, Lead, Pharmaceutical industry

SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.

Key Points:

SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
Ms. Sandra Zeng has been appointed Chief Medical Officer in charge of the clinical development team and cross function collaboration to bring more in-house developed and in-licensed innovative products in China.
Mr. Rico Liang has been appointed Chief Product Officer overseeing the Company's medical affairs and marketing departments.
We welcome Ms. Zeng and Mr. Liang as our new Chief Medical Officer and Chief Product Officer who bring to Everest decades of relevant global and China experience to help accelerate our strategic growth goals," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.

Rare Disease Advocates Learn to Accelerate Therapeutic Development at 9th RARE Drug Development Symposium

Retrieved on:

Thursday, March 14, 2024

Research, Organization, NCATS, Global Genes, Learning, Disease, Science, Caregiver, University, Patient, Knowledge, Data collection, Drug development, Division, Amgen, Food, Pharmaceutical industry

ALISO VIEJO, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- The rare disease patient advocacy organization Global Genes and the Orphan Disease Center at the University of Pennsylvania will host the 9th Annual RARE Drug Development Symposium, an event that provides patient advocates with the knowledge, skills, and connections they need to advance therapeutic development for their communities.

Key Points:

ALISO VIEJO, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- The rare disease patient advocacy organization Global Genes and the Orphan Disease Center at the University of Pennsylvania will host the 9th Annual RARE Drug Development Symposium, an event that provides patient advocates with the knowledge, skills, and connections they need to advance therapeutic development for their communities.
"Since Global Genes and the Orphan Disease Center launched the RARE Drug Development Symposium nine years ago, patient advocates have emerged as critical catalysts and drivers of therapeutic development," said Charlene Son Rigby, CEO of Global Genes.
Sponsors for this year's RARE Drug Development Symposium include Alexion , Amgen , Amicus Therapeutics , BioCryst , BridgeBio , Ovid Therapeutics , and Sanofi Genzyme .
"Rare disease patient communities are active participants in the drug development process," said Monique Molloy, Executive Director, Orphan Disease Center at the University of Pennsylvania.

Revelation Partners Expands Team and Promotes Internal Talent

Retrieved on:

Wednesday, March 13, 2024

Growth, Associate, SVB, Ross School of Business, University, Revelation, Marketing, Cowen Inc., Investment, Initial public offering, Multimedia, Amgen, Accounting, Video game

SAUSALITO, Calif., March 11, 2024 /PRNewswire/ -- Revelation Partners announced today it is expanding its team as well as promoting internal talent.

Key Points:

SAUSALITO, Calif., March 11, 2024 /PRNewswire/ -- Revelation Partners announced today it is expanding its team as well as promoting internal talent.
"We're excited to add an experienced Associate to the healthcare investment team at Revelation," said Mike Boggs, Managing Partner.
In addition to the new hires, Revelation Partners is pleased to highlight the promotion of three team members in 2023.
We're always proud to celebrate the growth of internal talent and recognize team members who help us grow the firm and make good investments -- this marks no exception," added Mike Boggs.

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Retrieved on:

Monday, March 11, 2024

Therapy, Amgen, Safety, CD19, Breast, ASX, Ovary, Patient, OASIS, IMU, Blinatumomab, Melanoma, Vaccine

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

Key Points:

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
The trial is titled: “A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors.” See https://clinicaltrials.gov/study/NCT06063317
The combination arm of the study will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen which currently is specifically approved only for liquid blood cancers).
onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto® therapy alone and will represent a paradigm shift in solid tumour treatment.
OASIS is a dose escalation trial that will be conducted across multiple sites across the United States, with 52 patients proposed to take part in the trial.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, March 11, 2024

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points:

Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Retrieved on:

Monday, March 11, 2024

CHRO, Amgen, Head, Kythira, Workforce, Management

WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer (CHRO), effective immediately.

Key Points:

WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer (CHRO), effective immediately.
Mr. Tucker joined Arcutis in July 2020 as executive director and head of human resources and was promoted to vice president of human resources in March 2022.
Prior to joining Arcutis, he held leadership roles in human resources and employee management at multiple pharmaceutical companies including Atara Biotherapeutics, Sienna Biopharmaceuticals, and Kythera.
Prior, he functioned as senior director and head of human resources at Sienna Biotherapeutics, where he established and led the human resources function as the company transitioned from a private to a publicly traded company.

United in the Fight Against Colorectal Cancer

Retrieved on:

Thursday, March 7, 2024

Breast cancer, Incidence, American Cancer Society, Woman, Amgen, ACS, CRC, Patient, Mortality, Colorectal cancer, Research, Exact sciences

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.

Key Points:

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.
Despite these escalating rates, there has been a lack of progress in developing effective treatment options for colorectal cancer patients, and persistent health disparities in incidence, mortality, and survivorship rates continue to exist.
United in Blue serves as a visual reminder for policymakers, emphasizing the necessity of increasing research funding for colorectal cancer and implementing a comprehensive plan to address the needs of the community.
Fight CRC’s United in Blue installation is sponsored by Amgen and Exact Sciences.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on:

Wednesday, February 28, 2024

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points:

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
“We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer

Retrieved on:

Tuesday, February 27, 2024

Therapy, Oracle, Research, Amgen, Drug development, T-cell lymphoma, University, CD5, Patient, Internal medicine, Drug, Disease, Biology, Infection, Nursing

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer.

Key Points:

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer.
“Drawing on her extensive expertise in the oncology and hematology drug development ecosystem, Dr. Mazanet will be an invaluable asset to Vittoria’s executive team as we enter first-in-human studies for our lead program,” said Nicholas Siciliano, Ph.D., Vittoria’s Chief Executive Officer.
Vittoria’s innovative approach to CAR-T development could change the treatment paradigm for T-cell lymphoma patients struggling with this debilitating disease.
Dr. Mazanet received her clinical training in internal medicine and oncology at Harvard Hospitals.

NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2024

Retrieved on:

Wednesday, February 21, 2024

Reached the milestone of 500 AI-powered RTX games and applications utilizing NVIDIA DLSS, ray tracing and other NVIDIA RTX technologies.

Key Points:

Reached the milestone of 500 AI-powered RTX games and applications utilizing NVIDIA DLSS, ray tracing and other NVIDIA RTX technologies.
NVIDIA will conduct a conference call with analysts and investors to discuss its fourth quarter and fiscal 2024 financial results and current financial prospects today at 2 p.m. Pacific time (5 p.m. Eastern time).
The webcast will be recorded and available for replay until NVIDIA’s conference call to discuss its financial results for its first quarter of fiscal 2025.
NVIDIA believes the presentation of its non-GAAP financial measures enhances the user’s overall understanding of the company’s historical financial performance.